Business Wire

CE Mark for MEVION S250i Proton Therapy System

Del

Mevion Medical Systems announced today that the MEVION S250i Proton Therapy System® has achieved CE Marking clearance. CE Marking permits clinical use of the system within the European Union and any country that recognizes the CE Mark. The MEVION S250i system includes HYPERSCAN™ technology, the next generation of pencil beam scanning (PBS) for faster, sharper, and more robust proton treatments.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171113005323/en/

The first European MEVION S250i proton therapy system installation will be completed in 2018 at the  ...

The first European MEVION S250i proton therapy system installation will be completed in 2018 at the Zuid-Oost Nederland Protonen Therapie Centrum (ZON PTC) at the Maastro Clinic in Maastricht, the Netherlands. (Photo: Business Wire)

“This milestone is part of Mevion’s global expansion of cutting-edge compact proton therapy systems in Europe,” said Perjan Pleunis, Field VP of Business Development (EMEA). “Mevion has led the way in establishing compact proton therapy as the most technologically advanced and financially viable choice in proton therapy.” European CE Marking is the first regulatory clearance for the MEVION S250i system. Mevion also submitted for US FDA 510(k) clearance in September.

First European Installation
The first European MEVION S250i proton therapy system installation will be completed in 2018 at the Zuid-Oost Nederland Protonen Therapie Centrum (ZON PTC) at the Maastro Clinic in Maastricht, the Netherlands.

The MEVION S250i system will be the first of its kind in Europe. Designed to deliver faster, sharper, and more robust treatments, the HYPERSCAN PBS technology incorporates the fastest energy layer switching, optimized spot sizes, and the Adaptive Aperture™ proton multi-leaf collimator system. This capability provides dose gradient advantages with up to a three times sharper lateral penumbra reducing dose uncertainty at the edge of the tumor thus sparing healthy tissue and preventing unnecessary radiation to sensitive locations. This improved precision in delivery is combined with hyper-fast beam delivery reducing the sensitivity to motion that current PBS technologies face when treating moving lesions such as those in the thoracic cavity.

Built on Leading Compact Proton Therapy Technology
The MEVION S250i system is based on Mevion’s high efficiency, low financial risk S250 Series platform. The core technology of the S250 Series includes the world’s only gantry mounted superconducting synchrocyclotron, a six degree-of-freedom treatment couch and advanced in-room IGRT imaging, all leveraged in the S250i system. This compact, fully integrated platform has years of successful clinical experience, proven financial viability and now delivers next generation pencil beam scanning.

The MEVION S250i lowers the cost per patient by reducing capital costs, reducing operating costs, and increasing treatment throughput. Mevion customers have achieved the fastest per-room patient ramp-up in the history of proton therapy. High throughput is achieved via linac-like workflow, low maintenance requirements, and industry-leading uptime. Demonstrating that compact proton therapy is a viable option for any size cancer center is core to Mevion’s mission of making proton therapy accessible to as many patients as possible.

About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in the Europe, Japan and China. For more information, please visit www.mevion.com.

Follow Mevion on Twitter: https://twitter.com/mevionmedical

Connect with Mevion on LinkedIn: https://www.linkedin.com/company/mevion-medical-systems

About the MEVION S250™ Series
The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefiting from Mevion’s patented Direct Dose™ beam delivery technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers.

The MEVION S250 Series includes:

  • MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities
  • MEVION S250i Proton Therapy System™ with HYPERSCAN™ technology, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed
  • MEVION S250mx™ options, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime

The MEVION S250i Proton Therapy System is 510(k) pending and has not been cleared by the USFDA for clinical use.

LPR171113

Contact information

Mevion
Melanie Benton, 978-540-1551
mbenton@mevion.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

inRiver Expands Executive Bench and Growth Initiatives for 201921.1.2019 07:00Pressemelding

inRiver, the leading provider of SaaS-based product information management (PIM) solutions, today elevated veteran sales executive Jimmy Jeppsson Bäckström to chief revenue officer, and promoted Johan Eriksson to chief financial officer, rounding out the executive team additions that included Thor Johnson, chief executive officer, Eric Waller, chief technology officer and executive vice president of product, Maria Bolmstedt, vice president of services, and Steve Gershik, chief marketing officer in 2018. The past year yielded tremendous growth for inRiver as the organization continued to strengthen its presence in North America and expand operations in Europe with 40% increase in new customer logos and more than 50% increase in recurring revenue. New customers in retail and branded manufacturing within the fashion, construction, accessories, medical devices, food and beverage, and furniture verticals have grown the inRiver community to over 1,500 brands and 500 customers globally. “Cust

Former Commander of the Estonian Defence Forces, Gen Riho Terras Joins Milrem Robotics’ Team21.1.2019 07:00Pressemelding

Gen (ret) Riho Terras who served as the Commander of the Estonian Defence Forces for 7 years and retired in December 2018 joins the team of one of the leading unmanned warfare systems developers Milrem Robotics to head up its Defence Division. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190120005004/en/ The CEO and owner of Milrem Robotics Kuldar Vaarsi (left) and the new Director of the Defence Division Gen (ret) Riho Terras. (Photo: Business Wire) General Terras’ main responsibilities will be establishing Milrem Robotics’ international business development and program support teams, leading the process of gaining a strong foothold in the defence market and bringing end-user specific know-how to company’s strategic R&D activities. “General Terras’ strong background and experience put him in a good position to grow the company’s international presence and build up our teams worldwide,” explained Kuldar Väärsi, CEO and own

MagicStay Launches a New Loyalty Program21.1.2019 07:00Pressemelding

MagicStay, the first apartment booking site dedicated to business travel and mobility, is launching its new Magic Loyalty Card program to reward traveler loyalty. MagicStay is the first French alternative accommodation booking site, created to meet the requirements of business travel (duty of care, date protection, travel policy…) and available for all those who wish to travel peacefully. The platform provides over 200 000 studios, apartments and houses in more than 90 countries. Collect points for every euro spent: When booking on MagicStay, for every euro spent, customers will receive one loyalty point. Put forward to simplify and personalize customer experience, the program allows travelers to spend the collected points as they wish: discount on future reservations, gifts or donations to charitable organizations. Each customer will be able to consult their loyalty points on their personal space on www.magicstay.com and transform them at any time. This loyalty program is intended for

US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States20.1.2019 23:38Pressemelding

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1 (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. Please see Boxed Warnings and Important Safety Information for ONTRUZANT® below. ONTRUZANT® is Samsung Bioepis’ first oncology biosimilar to receive FDA approval, and will be marketed and distributed in the United States (US) by Merck, which is known as MSD outside of the US and Canada. “For many cancer patients in the US, battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment. Biosimilars are intended to be lower cost, high-quality treatment options that have the potential t

More4Apps to Join the Cloud20.1.2019 22:53Pressemelding

More4Apps, the NZ-based software integration specialist known for its Excel based Oracle EBS integration tools, has confirmed it will be building product for Cloud ERP. “We're overwhelmed by the number of customers asking for our solutions to be migrated to the new ERP system, and that’s driven our strategic commitment to developing Cloud-based data entry tools,” said Bruce Doig, co-founder and Head of Innovation at More4Apps. “Already we have a large team working closely with a well known US fast food restaurant chain to deliver several loaders integrated with Oracle ERP Cloud.” As a Gold Partner with Oracle, More4Apps is well positioned to develop a range of integration tools for the new platform, with an intimate knowledge of the existing EBS and a close working relationship with a customer with whom they are collaborating to develop data loaders for the new SaaS platform. And whilst the capabilities of Cloud ERP are yet to be fully proven, More4Apps are confident there will be a pl

Warm welcome for ABB Formula E in Davos19.1.2019 09:00Pressemelding

Just a few days before the start of the World Economic Forum 2019, Davos is celebrating a world premiere: The latest ABB FIA Formula E racing car - dubbed Gen2 – was transported on a train from the iconic Swiss Rhaetian Railway to Europe’s highest city, where it will be an exciting eyecatcher during the coming week at the Davos Platz railway station. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190119005003/en/ ABB FIA Formula E racing car in Davos (Photo: Business Wire) From this Saturday until next Sunday, January 27, the Gen2 will be on display in a special glass case. Interested passersby can learn about the ABB FIA Formula E racing series as well as about the activities of ABB in e-mobility via an information system. With over 8,500 fast charging stations installed in 70 countries around the world, ABB is the global market leader for charging infrastructures. To watch the video, click here ABB (ABBN: SIX Swiss Ex) is